Abera Bioscience AB (NGM: ABERA)

Market Cap	70.47M
Revenue (ttm)	12.60M
Net Income (ttm)	-3.72M
Shares Out	15.35M
EPS (ttm)	-0.26
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	12,727
Open	4.440
Previous Close	4.000
Day's Range	4.010 - 4.500
52-Week Range	3.510 - 7.500
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Feb 7, 2025

About Abera Bioscience AB

Abera Bioscience AB, a platform and vaccine development company, research, design, and develops vaccines and immunotherapies based on its proprietary vaccine delivery platform in Sweden and internationally. The company’s development platform named BERA, uses for the display of antigens at the surface of outer membrane vesicles derived from genetically optimized gram-negative bacteria. Its lead vaccine candidate is a universal pneumococcal vaccine based on the platform BERA. The company also develops projects in immuno-oncology, Chlamydia, ETEC,...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 2012
• Employees: 6
• Stock Exchange: Nordic Growth Market
• Ticker Symbol: ABERA

Financial Performance

In 2023, Abera Bioscience AB's revenue was 2.52 million, an increase of 41.21% compared to the previous year's 1.79 million. Losses were -16.72 million, -13.74% less than in 2022.